Mallinckrodt to Post Q1 2018 Earnings of $1.18 Per Share, SunTrust Banks Forecasts (MNK)

Mallinckrodt (NYSE:MNK) – SunTrust Banks issued their Q1 2018 earnings per share estimates for Mallinckrodt in a report released on Wednesday, April 11th. SunTrust Banks analyst J. Boris forecasts that the company will post earnings of $1.18 per share for the quarter. SunTrust Banks currently has a “Hold” rating and a $15.00 target price on the stock. SunTrust Banks also issued estimates for Mallinckrodt’s Q2 2018 earnings at $1.51 EPS, Q3 2018 earnings at $1.58 EPS, Q4 2018 earnings at $1.80 EPS, FY2018 earnings at $6.07 EPS, FY2019 earnings at $6.27 EPS, FY2020 earnings at $7.20 EPS, FY2021 earnings at $6.86 EPS and FY2022 earnings at $7.87 EPS.

How to Become a New Pot Stock Millionaire

Mallinckrodt (NYSE:MNK) last released its quarterly earnings data on Tuesday, February 27th. The company reported $2.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.72 by $0.29. The firm had revenue of $792.30 million for the quarter, compared to the consensus estimate of $769.91 million. Mallinckrodt had a return on equity of 13.43% and a net margin of 66.25%. The company’s quarterly revenue was down 4.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.91 earnings per share.



MNK has been the topic of several other research reports. ValuEngine downgraded Mallinckrodt from a “hold” rating to a “sell” rating in a report on Monday, April 2nd. Wells Fargo reiterated a “hold” rating on shares of Mallinckrodt in a report on Thursday, April 12th. Goldman Sachs reiterated a “hold” rating on shares of Mallinckrodt in a report on Tuesday, December 26th. Canaccord Genuity set a $24.00 price objective on Mallinckrodt and gave the stock a “hold” rating in a report on Sunday, January 7th. Finally, Oppenheimer reiterated a “hold” rating on shares of Mallinckrodt in a report on Tuesday, February 27th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $33.89.

MNK opened at $13.97 on Monday. The stock has a market capitalization of $1,190.77, a PE ratio of 1.87, a P/E/G ratio of 0.34 and a beta of 1.12. The company has a current ratio of 2.18, a quick ratio of 1.85 and a debt-to-equity ratio of 0.98. Mallinckrodt has a 12 month low of $13.32 and a 12 month high of $49.12.

A number of institutional investors have recently bought and sold shares of the business. Macquarie Group Ltd. boosted its position in Mallinckrodt by 62.7% during the 4th quarter. Macquarie Group Ltd. now owns 58,422 shares of the company’s stock valued at $9,069,000 after acquiring an additional 22,507 shares in the last quarter. LPL Financial LLC bought a new stake in Mallinckrodt during the 4th quarter valued at approximately $1,718,000. Sciencast Management LP bought a new stake in Mallinckrodt during the 4th quarter valued at approximately $210,000. Two Sigma Investments LP bought a new stake in Mallinckrodt during the 4th quarter valued at approximately $30,841,000. Finally, Two Sigma Advisers LP bought a new stake in Mallinckrodt during the 4th quarter valued at approximately $24,007,000.

ILLEGAL ACTIVITY WARNING: This article was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://stocknewstimes.com/2018/04/18/mallinckrodt-to-post-q1-2018-earnings-of-1-18-per-share-suntrust-banks-forecasts-mnk.html.

Mallinckrodt Company Profile

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.

Earnings History and Estimates for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply